Frontiers Association of Lipoprotein(a)-Associated Mortality and

Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels

Non-Traditional Risk Factors as Contributors to Cardiovascular Disease

Biomedicines, Free Full-Text

LP(a), cardiovascular disease, and all-cause mortality: What's optimal?

The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study [PeerJ]

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention

Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study: Molecular Therapy - Methods & Clinical Development

Lipoprotein(a): The next frontier in CV risk reduction

Full article: Lipoprotein(a): cardiovascular risk and emerging therapies

Frontiers Serum lipoprotein (a) associates with the risk of renal function damage in the CHCN-BTH Study: Cross-sectional and Mendelian randomization analyses